Page 3 - Between Jun News Today : Breaking News, Live Updates & Top Stories | Vimarsana

1. Median progression-free survival in the HSCT group was significantly longer than in the non-HSCT group. 2. HSCT was associated with a slightly increased risk of serious adverse events, including graft-versus-host disease (59% vs. 44%, respectively). Evidence Rating Level: 2 (Good) Study Rundown: Advanced cutaneous T-cell lymphoma (CTCL) is a rare and aggressive form of

1. Median progression-free survival in zolbetuximab group was greater than in the placebo group (10.6 months vs. 8.7 months). 2. There were significantly more serious adverse events in the Zolbetuximab group with nausea, vomiting, and decreased appetite being the most common symptoms. Evidence Rating Level: 1 (Excellent) Study Rundown: First-line treatment for gastric and gastro-esophageal

1. In both ELEVATE UC 12 and ELEVATE UC 52, significantly greater patients in the etrasimod group achieved clinical remission compared to placebo. 2. Majority of adverse events were mild-to-moderate in nature with no reported fatalities. Evidence Rating Level: 1 (Excellent) Study Rundown: Ulcerative colitis is a chronic, autoimmune disease of the gastrointestinal tract that affects many

1. The immediate revascularization group met the noninferiority criteria for the primary composite outcome, but superiority at the 1-year follow-up was not met. 2. A marked reduction in myocardial infarction was noted in the immediate revascularization group compared to the staged revascularization group. Evidence Rating Level: 1 (Excellent) Study Rundown: In patients with acute coronary

1. In both ELEVATE UC 12 and ELEVATE UC 52, significantly greater patients in the etrasimod group achieved clinical remission compared to placebo. 2. Majority of adverse events were mild-to-moderate in nature with no reported fatalities. Evidence Rating Level: 1 (Excellent) Study Rundown: Ulcerative colitis is a chronic, autoimmune disease of the gastrointestinal tract that